Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

Lancet

Volumn 353, Issue 9153, 1999, Pages 611-616

  Hansson, Lennart ^a   Lindholm, Lars H ^b   Niskanen, Leo ^c   Lanke, Jan ^d   Hedner, Thomas ^e   Niklason, Anders ^f   Luomanmäki, Kimmo ^g   Dahlöf, Björn ^h   De Faire, Ulf ⁱ   Mörlin, Claes ^f   Karlberg, Bengt E ^j   Wester, P O ^b   Björck, Jan Erik ^f  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d LUND UNIVERSITY   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f BRISTOL MYERS SQUIBB   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

^h GU Clinical Research Institute   (Sweden)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FINLAND; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; SWEDEN;

EID: 0033034404     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)05012-0     Document Type: Article

References (35)

1. Zanchetti A, Chalmers J, Arakawa K, et al. The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press 1993; 2: 86-100.
2. The 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023-28.
3. The Joint National Committe on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
4. The Joint National Committee on Detction, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-46.
5. The CAPPP Group. The Captopril Prevention Project: a prospective interventional trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertension 1990; 8: 985-90.
6. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease - part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
7. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
8. Schmieder RE, Marttus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13.
9. Levy D. Left ventricular hypertrophy: epidemiological insights from the Framingham Heart Study. Drug 1988; 35 (suppl 5): 1-5.
10. Levy D, Garrison RJ, Sagae DD, Kannel WB, Castelli WP. Prognostic implications of echo cardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-66.
11. Pfeffer MA, Braunwald E, Moyé LA, et al, for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77.
12. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; i: 225-59.
13. Pollare T, Lithell H, Berne C. A comparison of the effect of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73.
14. Croogh, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1984; 314: 1657-64.
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
16. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
17. Himmelman A, Hansson L, Hansson B-G, et al. ACE inhibitors preserves renal function better than beta-blockers in the treatment of essential hypertension. Blood Press 1995; 4: 85-90.
18. Himmelman A, Hansson L, Hansson B-G, et al. Long-term renal preservation in essential hypertension: ACE inhibition superior to beta-blockade. Am J Hypertens 1996; 9: 850-53.
19. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) Study; a novel design for intervention trials. Blood Press 1992; 1: 113-19.
20. Hansson L, Hedner T, Lindholm, L, et al, for the CAPPP Study Group. The Captopril Prevention Projection (CAPPP) in hypertension: baseline data and current status. Blood Press 1997; 6: 365-67.
21. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
22. Dahlöf B, Lindholm LH, Hansson L, Scherstën B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-85.
23. The MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405.
24. Cook NR, Cohen J, Hekbert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-09.
25. McInnes GT, Holes DJ, Murray LS, et al. Do ACE inhibitors reduce mortality in hypertensive patients? Amsterdam: ISH, June 1998 (abstr).
26. Lindholm LH, Hansson L, Dahlöf B, et al. The Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-2): progress report. Blood Press 1996; 5: 300-04.
27. Alleman Y, Baumann S, Jost M, et al. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. EurJ Clin Pharmacol 1992; 42: 275-80.
28. Santoro D, Natali A, Palombo C, et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992; 20: 181-91.
29. Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Metabolic effects during lisinopril/bendrofluazide treatment: results from a randomised, double-blind study with parallel groups. Milan: Sixth European Society of Hypertension meeting, 1993 (abstr).
30. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
31. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. BMJ 1998; 317: 693-94.
32. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects on initial drug choice and comorbidity on antihypertensive drug compliance. Am J Hypertens 1997; 10: 697-704.
33. McCombs JS, Nichol M, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a medicaid population. Med Care 1994; 32: 214-26.
34. Hilleman DE, Nohiuddin SM, Lucas Jr BD, Stading JA, Stoysich AM, Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16: 88-102.
35. Elliot WJ. Costs associated with changing antihypertensive drug monotherapy: "preferred" vs "alternative" therapy. Am J Hypertens 1995; 8: 80A (abstr F11).